UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand

Internal medicine journal, 2020-06, Vol.50 (6), p.716-725

2020

Volltextzugriff (PDF)

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Blood cancer journal (New York), 2021-02, Vol.11 (2), p.19-19, Article 19

2021

Volltextzugriff (PDF)

Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia

PloS one, 2008-05, Vol.3 (5), p.e2141-e2141

2008

Volltextzugriff (PDF)

ATR-16 syndrome: mechanisms linking monosomy to phenotype

Journal of medical genetics, 2020-06, Vol.57 (6), p.414-421

2020

Volltextzugriff (PDF)

Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2

Genes chromosomes & cancer, 2003-05, Vol.37 (1), p.72-78

2003

Volltextzugriff (PDF)

53. Uveal melanoma - The New Zealand perspective

Cancer genetics, 2023-11, Vol.278-279, p.16-17

2023

Volltextzugriff (PDF)

Incorporation of COVID-19 variant testing within a community laboratory using the TaqMan SARS-CoV-2 Mutation Panel

New Zealand journal of medical laboratory science, 2022-11, Vol.76 (3)

2022

Volltextzugriff (PDF)

59. What the TERT? - A telomerase reverse transcriptase case study

Cancer genetics, 2024-08, Vol.286-287, p.S19-S19

2024

Volltextzugriff (PDF)

Determining the optimal input DNA concentration range for AmpFLSTR® identifier™ assay

New Zealand journal of medical laboratory science, 2023-01, Vol.77 (3), p.145-146

2023

Volltextzugriff (PDF)

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal Carcinoma

Applied immunohistochemistry & molecular morphology, 2017-08, Vol.25 (7), p.475-480

2017

Volltextzugriff (PDF)

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.106-106

2024

Volltextzugriff (PDF)

10. Uveal melanoma: The New Zealand perspective

Cancer genetics, 2020-06, Vol.244, p.4-4

2020

Volltextzugriff (PDF)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

British journal of haematology, 2019-08, Vol.186 (4), p.549-560

2019

Volltextzugriff (PDF)

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Blood, 2022-11, Vol.140 (Supplement 1), p.2108-2109

2022

Volltextzugriff (PDF)

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.8513-8513

2020

Volltextzugriff (PDF)

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2759-2759

2021

Volltextzugriff (PDF)

Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14030-e14030

2020

Volltextzugriff (PDF)

Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20 (9), p.e543-e546

2020

Volltextzugriff (PDF)

Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8011-8011

2021

Volltextzugriff (PDF)

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Blood, 2020-11, Vol.136 (Supplement 1), p.50-50

2020

Volltextzugriff (PDF)

Validation of a molecular assay to detect SARS-CoV-2 in saliva

New Zealand medical journal, 2021-12, Vol.134 (1547), p.34-47

Pitman, Janet L

2021

Volltextzugriff (PDF)

39 - Evaluation of Integrating HD-SNP Microarray Into the Workflow for CLL and MM: Challenges and Culture Changes

Cancer genetics, 2017-08, Vol.214-215, p.44-44

2017

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(51)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non‐small‐cell lung cancer in New Zealand

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia

ATR-16 syndrome: mechanisms linking monosomy to phenotype

Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2

53. Uveal melanoma - The New Zealand perspective

Incorporation of COVID-19 variant testing within a community laboratory using the TaqMan SARS-CoV-2 Mutation Panel

59. What the TERT? - A telomerase reverse transcriptase case study

Determining the optimal input DNA concentration range for AmpFLSTR® identifier™ assay

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal Carcinoma

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

10. Uveal melanoma: The New Zealand perspective

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic

Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic

Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM)

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Validation of a molecular assay to detect SARS-CoV-2 in saliva

Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

39 - Evaluation of Integrating HD-SNP Microarray Into the Workflow for CLL and MM: Challenges and Culture Changes

Suchergebnisse filtern